ライフサイエンスコーパス: Netherlands

1 d SCD patients were combined (France and The Netherlands).

2 rmany) and the Cassini (i-Optics, The Hague, Netherlands).

3 VU University Medical Center (Amsterdam, the Netherlands).

4 United States), and the Rotterdam Study (the Netherlands).

5 ch organization (Cardialysis, Rotterdam, the Netherlands).

6 nquin Biologicals Laboratory, Amsterdam, The Netherlands).

7 SAplus and MAS (Germany), and PIAMA-NHS (the Netherlands).

8 Three large tertiary care ICUs in the Netherlands.

9 y Refeeding (MOTHER)] in 19 hospitals in the Netherlands.

10 idation R(2) was 53% in Basel and 50% in The Netherlands.

11 nder current vaccine costs and uptake in the Netherlands.

12 cancer during the introduction of MIG in the Netherlands.

13 n Germany, Italy, Singapore, Israel, and the Netherlands.

14 gical ICU of a tertiary care hospital in the Netherlands.

15 on plant, as well as in other regions in The Netherlands.

16 pertrophic cardiomyopathy (HCM) cases in the Netherlands.

17 l ICU of two large teaching hospitals in the Netherlands.

18 pective cohort from fetal life onward in the Netherlands.

19 onation after circulatory death (DCD) in the Netherlands.

20 ine dose is given at 14 months of age in the Netherlands.

21 tors for venous thrombosis, conducted in the Netherlands.

22 h IRD from 2 ophthalmogenetic centers in the Netherlands.

23 declining incidence trend of dementia in the Netherlands.

24 as in river water from control sites, in The Netherlands.

25 CCSs diagnosed between 1963 and 2001 in the Netherlands.

26 r Treatment for Acute Ischemic Stroke in the Netherlands.

27 tional Center for Blistering Diseases in The Netherlands.

28 plantation in 2 high-volume hospitals in the Netherlands.

29 1 rheumatology outpatient departments in the Netherlands.

30 -2014, a measles outbreak spread through the Netherlands.

31 rent acute teaching-hospital settings in the Netherlands.

32 community and 2 university hospitals in the Netherlands.

33 ative Ocular Surgery (NIIOS), Rotterdam, the Netherlands.

34 r treatment for acute ischemic stroke in the Netherlands.

35 on-IVF group) from all 12 IVF clinics in the Netherlands.

36 measurements in Amsterdam and Rotterdam, The Netherlands.

37 rom the Myopia Study (2010 to 2012) from the Netherlands.

38 e ICUs of two tertiary care hospitals in the Netherlands.

39 n some jurisdictions such as Belgium and the Netherlands.

40 e Rotterdam Ophthalmic Institute, Rotterdam, Netherlands.

41 minant in fish in Canada and possibly in The Netherlands.

42 the Academic Medical Center, Amsterdam, the Netherlands.

43 many, Singapore, Spain, Switzerland, and the Netherlands.

44 ertiary care referral center in Utrecht, the Netherlands.

45 the USA, UK, Canada, Spain, France, and the Netherlands.

46 e United States, the United Kingdom, and the Netherlands.

47 e prevalence was previously reported for the Netherlands.

48 general, nonfarming, rural population in the Netherlands.

49 r End-Stage Disease) study in Groningen, the Netherlands.

50 Two tertiary mixed ICUs in The Netherlands.

51 in 16 multidisciplinary pain clinics in the Netherlands.

52 2014 through October 2015 in Maastricht, The Netherlands.

53 eration R, a prospective birth cohort in the Netherlands.

54 thin eight gynecologic cancer centers in the Netherlands.

55 ary and tertiary care centers throughout the Netherlands.

56 t academic and non-academic hospitals in the Netherlands.

57 nits following alerts in Switzerland and The Netherlands.

58 d lifestyle programs, in 15 hospitals in the Netherlands.

59 astrectomy in three bariatric centers in the Netherlands.

60 16 hospitals in the Netherlands.

61 tiary dry eye clinic patient cohort from the Netherlands.

62 cs of CDI among hospitalized children in the Netherlands.

63 C-Sophia Children's Hospital, Rotterdam, the Netherlands.

64 e use of MIG increased from 4% to 53% in the Netherlands.

65 , and development of PCP cooperatives in the Netherlands.

66 the largest health insurance provider in the Netherlands.

67 University hospital in the Netherlands.

68 xed ICUs of 2 tertiary care hospitals in the Netherlands.

69 W cc11 (MenW:cc11) emerged in 2012-13 in the Netherlands.

70 provide specialist mental health care in the Netherlands.

71 admissions from 2 tertiary hospitals in the Netherlands.

72 care records from a large population in the Netherlands.

73 formation on causes of death from statistics Netherlands.

74 of the Generation R Study in Rotterdam, the Netherlands (2002-2012), among 3,748 pregnant mothers an

75 In the Netherlands (2005 to 2013) only 10% of distal pancreatec

76 Five level I trauma centers in the Netherlands (2008-2009).

77 d titers >160 to A/Shanghai/2/13 (H7N9) or A/Netherlands/219/03 (H7N7).

78 erent H7 viruses [A/Shanghai/2/2013(H7N9), A/Netherlands/219/2003(H7N7), and A/New York/107/2003(H7N2

79 cross the complete genome of the HPAI H7N7 A/Netherlands/33/03 virus.

80 inoculated with H1N1pdm09 influenza virus A/Netherlands/602/09 by the intranasal or intratracheal ro

81 with substitutions in the hemagglutinin of A/Netherlands/602/09 in an attenuated backbone to explore

82 nama/2007/99 (H3N2) and pandemic influenza A/Netherlands/602/2009 (H1N1) viruses.

83 olled from 4 tertiary medical centers in the Netherlands, 66 eyes were studied.

84 In the Netherlands, a pilot FIT-based biennial CRC screening pr

85 or perinatal mortality, was observed in the Netherlands after extension of the smoke-free workplace

86 tem of Eindhoven and the Dommel River in The Netherlands, against the base case, "do-nothing" option.

87 , and San Francisco), Canada (Montreal), the Netherlands (Amsterdam), and Australia (Sydney and Melbo

88 ysicians, and death certificate studies (the Netherlands and Belgium) were reviewed for the period 19

89 In the Netherlands and Belgium, about half or more of physician

90 tertiary and nine teaching hospitals in the Netherlands and Belgium.

91 dent clinical research organisations) in the Netherlands and Denmark with fasting LDL cholesterol lev

92 ZonMw, The Netherlands and Dr Hans Ludwig Geisenhofer Foundation, G

93 l serogroup W and serogroup C disease in the Netherlands and England for the epidemiological years (J

94 ons between the serogroup W outbreaks in the Netherlands and England, and the historical serogroup C

95 ate in Germany and Belgium, and lower in the Netherlands and England.

96 he Maastricht Cardiomyopathy Registry in the Netherlands and excluded patients with ischemic, valvula

97 arge peripheral or academic hospitals in The Netherlands and followed for at least one year.

98 population-based cohorts of elderly from the Netherlands and Germany (n = 13,044).

99 lysis of 41 samples collected in 2015 in the Netherlands and Germany.

100 nt communities of Gabon, Ghana, Ecuador, the Netherlands and Germany.

101 l 2100 at the scales of Europe, and Belgium, Netherlands and Luxembourg (BENELUX).

102 eeded for public health interventions in the Netherlands and other affected countries to prevent furt

103 The Netherlands and Slovenia had the highest treatment volum

104 of adult European honey buzzards between the Netherlands and sub-Saharan Africa, and find that they m

105 ertaken outside of North America; one in the Netherlands and the other in Uganda.

106 g hospitals and tertiary care centres in the Netherlands and the UK, adults with non-stricturing, ile

107 countries (Belgium, Switzerland, France, the Netherlands and the United Kingdom) and estimated the he

108 ntries (Bulgaria, Greece, Norway, Spain, the Netherlands and the United Kingdom) participated in the

109 tween Erasmus Medical Center, Rotterdam, the Netherlands and the University of Washington, Seattle) f

110 y using the number of burglaries suffered in Netherlands and then by using the number of volcanic eru

111 National incidences ranged from 1% (in the Netherlands and UK) to <0.3% (in Lithuania, Germany and

112 re derived from the PHARMO database network (Netherlands) and linked to patients diagnosed with colon

113 01 microarray (Check-Points, Wageningen, the Netherlands) and published multiplex PCR assays.

114 gh the HCHWA-D patient association (Katwijk, Netherlands) and the outpatient clinic of the Department

115 unit (Ingenia; Philips Healthcare, Best, the Netherlands) and two different 3.0-T units (750 W [GE He

116 ton, MA, USA), at Leiden University (Leiden, Netherlands), and at sites contributing to Alzheimer's D

117 ective ALS registers (Ireland, Italy and the Netherlands), and clinical data sets in the UK and Belgi

118 he Leiden University Medical Center (Leiden, Netherlands), and healthy controls.

119 land, the rate of increase was higher in the Netherlands, and age distributions were similar in both

120 the STI outpatient clinic in Amsterdam, the Netherlands, and analyzed their cervicovaginal samples a

121 9, 2006, to April 26, 2013, in Nijmegen, the Netherlands, and Cologne, Germany.

122 rth and South America, Germany, Switzerland, Netherlands, and France, the meeting was well attended.

123 liminated, such as the United States and the Netherlands, and measles remains endemic in some countri

124 stralia, Italy, the USA, the UK, Canada, the Netherlands, and New Zealand.

125 ist referral centres in the UK, Denmark, the Netherlands, and New Zealand.

126 LVE III) at 20 hospitals in Germany, France, Netherlands, and Poland.

127 tre trial (11 sites in Finland, Germany, the Netherlands, and Sweden), with optional 12-month double-

128 e countries (Australia, Canada, Denmark, the Netherlands, and the UK).

129 five countries (Belgium, Israel, Italy, the Netherlands, and the UK).

130 elated patients in Switzerland, Germany, the Netherlands, and the UK, 218 M chimaera isolates from va

131 (METOP) at 16 sites in Germany, France, the Netherlands, and the UK.

132 hospitals in the United Kingdom, Spain, the Netherlands, and the United States between 2009-2013 wer

133 tients and pigs with invasive disease in the Netherlands, and validated our observations with 18 comp

134 ceiving EAS for psychiatric disorders in the Netherlands are mostly women and of diverse ages, with c

135 7 to 2012 (n=95 240) were extracted from the Netherlands Association for Cardio-Thoracic Surgery data

136 btained from the ethical review board of the Netherlands Association for Medical Education.

137 data from the AIDS Therapy Evaluation in the Netherlands (ATHENA) nationwide HIV cohort.

138 cost-effective in the United States and the Netherlands began with coronary CT angiography, continue

139 Among HIV-infected patients in the Netherlands, being of SSA origin was associated with a h

140 ossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom) aims to evaluat

141 ossboss and Hybrid procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom) registry aims t

142 ossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom, RECHARGE regist

143 es (all departments of cardiology in the UK, Netherlands, Belgium, France, Germany, Austria, Denmark,

144 sted suicide can be legally practiced in the Netherlands, Belgium, Luxembourg, Colombia, and Canada (

145 women undergoing fertility treatment in the Netherlands between 1980 and 1995, IVF treatment compare

146 ited from six anticoagulation clinics in the Netherlands between 1999 and 2004; controls were their p

147 individuals from 499 families tested in The Netherlands between 1999 and 2014 (118 families met the

148 prospective cohort of 15,558 patients in the Netherlands between 2000 and 2010.

149 at the Leiden Anticoagulation Clinic in the Netherlands between 2003 and 2009 and experienced 1,683

150 cute HF were enrolled in 14 hospitals in the Netherlands between 2009 and 2014.

151 is to two intensive care units (ICUs) in the Netherlands between Jan 1, 2011, and July 20, 2012 (disc

152 All ICUs in the Netherlands between January 2009 and 2014 that participa

153 to two tertiary intensive care units in the Netherlands between January 2011 and June 2013, a total

154 centers in the greater Amsterdam area in the Netherlands between June 1, 2011, and June 15, 2015.

155 atory effects (n = 357, age: 4-12 years, the Netherlands), BREATHE (n = 820, age: 3-22 years, UK) and

156 arge dataset of HIV-infected patients in the Netherlands, but we believe that the overall patterns wi

157 l/food) obtained from Scotland, New Zealand, Netherlands, Canada and the USA.

158 ain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the USA, with the first cohort

159 tments was obtained through linkage with the Netherlands Cancer Registry (1989-2013).

160 mber of hematopoietic neoplasms based on The Netherlands Cancer Registry data was 3.0, resulting in a

161 The Netherlands Cancer Registry database (2005-2013) identif

162 SMNs were identified by linkages with the Netherlands Cancer Registry, the Dutch Pathology Registr

163 Using data from The Netherlands Cancer Registry, the expected number of hema

164 FIT screening, the cohort was linked to the Netherlands Cancer Registry, through March 31, 2015; par

165 between 2003 and 2008 were selected from the Netherlands Cancer Registry.

166 tween 2005 and 2014 were identified from the Netherlands Cancer Registry.

167 als of the coastal waters of Germany and the Netherlands, causing the death of thousands of animals.

168 43) and evaluated these factors in the NLCS (Netherlands Cohort Study; n = 383 cases).

169 tive Investigation into Cancer and Nutrition-Netherlands cohort.

170 In Belgium and the Netherlands, DCDs were responsible for 30% of deceased d

171 ervational cohort study was performed in the Netherlands during 2 winters.

172 , Ministry of Social Affairs and Employment (Netherlands), Economic and Social Research Council, US N

173 t 5 centers in United States and 1 center in Netherlands enrolled in the Barrett's Esophagus Study da

174 2007 and October 2011 in 19 hospitals in the Netherlands, enrolling 210 women with early breast cance

175 vestigation into Cancer and Nutrition in the Netherlands (EPIC-NL) study, plasma levels of protein-bo

176 sectional analysis of baseline data from the Netherlands Epidemiology of Obesity study, a population-

177 nal analysis of baseline measurements of the Netherlands Epidemiology of Obesity study, a population-

178 replicated in an independent cohort from the Netherlands (ERF).

179 muscle sample from the Western Scheldt, The Netherlands, FBSA concentration was at 80.12 ng/g wet we

180 linical trial conducted in Isala Zwolle, the Netherlands (February 2011-January 2015), involving pati

181 eptic shock in 2 intensive care units in the Netherlands from 2011 to 2015.

182 The relative increase in the Netherlands from 2014-15 to 2015-16 was 418% (95% CI 99-

183 o the Rome III criteria, at hospitals in The Netherlands from December 2009 to May 2014.

184 trial in 219 patients at 18 hospitals in The Netherlands from February 2008 through February 2013.

185 sions of more than 48 hours in 2 ICUs in the Netherlands from January 2011 to July 2013 stratified ac

186 1 of 6 neonatal intensive care units in the Netherlands from March 30, 2012, through August 17, 2014

187 countries (Canada, France, England, and the Netherlands) from which data were collected from January

188 er uveitis outpatient clinic, Rotterdam, the Netherlands, from April 3, 2013, through November 25, 20

189 ldus Information Technology, Wageningen, The Netherlands) gait analysis was significantly impaired in

190 prised all persons with CRC diagnosed in the Netherlands general population during the same period, i

191 earch Institute for Diseases in the Elderly; Netherlands Genomics Initiative; Netherlands Ministry of

192 ial (done in 13 study centres in Canada, the Netherlands, Germany, Denmark, and the UK), we assessed

193 ients, insurers, and policy makers) from the Netherlands, Germany, the United Kingdom, Ireland, Hunga

194 eroplasmy transmission in the Genomes of the Netherlands (GoNL) data, which consists of complete mtDN

195 tch individuals drawn from the Genome of the Netherlands (GoNL) study (0%, n=500; P<0.02).

196 Subsequently, the Netherlands has had an increase in the incidence of meni

197 l cancer, the Association of Surgeons of the Netherlands has stated a minimal annual volume standard

198 ore than half of the PCP cooperatives in the Netherlands have integrated with hospital emergency depa

199 studies in the United Kingdom (EMBRACE), the Netherlands (HEBON), and France (GENEPSO).

200 er investigated in cohorts from Iceland, the Netherlands, Hungary, Germany, and Italy, and a final me

201 ity mapping for an isolated community in the Netherlands identified a NEK1 p.Arg261His variant as a c

202 H7N7 virus occurred in poultry farms in The Netherlands in 2003.

203 First identified in The Netherlands in 2004, human coronavirus NL63 (HCoV-NL63)

204 anterior resection for rectal cancer in the Netherlands in 2011, with almost routine use of neoadjuv

205 ochemical tests (FITs), was initiated in The Netherlands in 2014.

206 ochemical tests (FITs), was initiated in The Netherlands in 2014.

207 g of commercially available dry pasta in the Netherlands in 2014.

208 ation-based prospective cohort in Rotterdam, Netherlands in 7098 mothers and their offspring.

209 nge and the implications for HIV care in the Netherlands in the future.

210 ple over these 100 years are men born in the Netherlands in the last quarter of 20th century, whose a

211 ter, randomized trial in 27 hospitals in the Netherlands in which infertile women who were undergoing

212 K from October 2007 to September 2012 at the Netherlands Institute for Innovative Ocular Surgery (NII

213 r Artisan Toric (Ophtec B.V., Groningen, The Netherlands) iris-fixated pIOL for the treatment of myop

214 xpansion of the MenW:cc11 2013 strain in the Netherlands, its high case fatality, and the availabilit

215 me Center Biobank, University of Tartu), the Netherlands (LifeLines Cohort Study), Sweden (Swedish Tw

216 sion of a workshop under the auspices of the Netherlands Lung Foundation to extend our understanding

217 whether plants imported to Ireland from the Netherlands might harbor triazole-resistant Aspergillus

218 he Elderly; Netherlands Genomics Initiative; Netherlands Ministry of Education, Culture and Science;

219 linda Gates Foundation, Rush Foundation, and Netherlands Ministry of Health, Welfare and Sport.

220 Ministry of Education, Culture and Science; Netherlands Ministry of Health, Welfare and Sports; Euro

221 r Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) in whom the carotid bifurcation c

222 ar Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) was a multicenter, randomized cli

223 r Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN).

224 n a genetically isolated population from the Netherlands (n = 1999).

225 the United States, Canada, Denmark, and The Netherlands (n = 6,271), we show that individuals who sp

226 cedents aged >65 years, N = 211,816) and the Netherlands (N = 7216) had the lowest proportion of dece

227 te European descent (Germany, n = 4,975; the Netherlands, n = 613; and Czech Republic, n = 521), and

228 ritical care units in the United States, the Netherlands, New Zealand, Australia, and Saudi Arabia.

229 a, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, UK, and

230 nada, Denmark, Germany, Hungary, Israel, the Netherlands, New Zealand, South Korea, Spain, Switzerlan

231 D-Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global h

232 Belgium, France, Greece, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Spain, and Massac

233 e), Amsterdam, Maastricht, and Utrecht ("The Netherlands"), Norwich (United Kingdom), Sabadell (Spain

234 ospitals (17 teaching and 2 academic) in the Netherlands (November 2014-September 2016), with a follo

235 da, England, Germany, and Norway than in the Netherlands or the United States.

236 he Academic Medical Center in Amsterdam, the Netherlands, or Inselspital University Hospital in Berne

237 rlands Organisation for Scientific Research; Netherlands Organisation for Health Research and Develop

238 ZonMw (the Netherlands Organisation for Health Research and Develop

239 The Netherlands Organisation for Health Research and Develop

240 Erasmus MC and Erasmus University Rotterdam; Netherlands Organisation for Scientific Research; Nether

241 g routine monitoring for GMOs in food in the Netherlands, papaya-containing food supplements were fou

242 ts with GBS admitted to hospitals across the Netherlands participating in national GBS studies from M

243 INATION trial, done in Italy, Spain, and the Netherlands, patients with ST-segment elevation myocardi

244 he United Kingdom (ALSPAC) and 3652 from the Netherlands (PIAMA).

245 centres in Belgium, France, Germany, Italy, Netherlands, Poland, and the UK.

246 e, Germany, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spai

247 en countries (Denmark, France, Italy, Japan, Netherlands, Portugal, and the UK) evaluated cases of di

248 s large population-based cohort study in the Netherlands refutes the finding from a previous report t

249 rope (Sweden [Stockholm and Gothenburg], the Netherlands [Rotterdam], the UK [England], and Spain [Za

250 f extracorporeal life support therapy in the Netherlands showed that mean total hospital cost of extr

251 al HIV cohort of all patients in care in the Netherlands since 1996 included HIV-1 subtype B polymera

252 es (Belgium, Bulgaria, Finland, Ireland, the Netherlands, Slovenia, and the Navarra region in Spain)

253 ction of key tobacco control policies in the Netherlands: smoke-free legislation in workplaces plus a

254 European (France, Belgium, Switzerland, the Netherlands, Spain) centers.

255 e individuals in Europe (France, Greece, the Netherlands, Spain, Switzerland, and the UK) and North a

256 Data were from 1530 patients of the Netherlands Study of Depression and Anxiety (NESDA) and

257 e Depression Genes Networks study (DGN), the Netherlands Study of Depression and Anxiety (NESDA), and

258 = 1792) were from two large cohort studies (Netherlands Study of Depression and Anxiety and Netherla

259 participants (aged 18 to 65 years) from the Netherlands Study of Depression and Anxiety with current

260 essment after 2 years, 515 patients from the Netherlands Study of Depression and Anxiety with past-ye

261 Data are from the Netherlands Study of Depression and Anxiety, including 2

262 ules measured in 1,676 participants from the Netherlands Study of Depression and Anxiety.

263 peripheral blood from 1848 subjects from The Netherlands Study of Depression and Anxiety.

264 trial done in Belgium, Denmark, Germany, the Netherlands, Sweden, the UK, and the USA.

265 In 2014 the Netherlands switched from 3 to 2 doses for routine vacci

266 entre phase 3 trial in Belgium, Germany, the Netherlands, Switzerland, France, Sweden, Austria, Italy

267 incidence started several years later in the Netherlands than in England, the rate of increase was hi

268 were part of a population-based study in the Netherlands, the Generation R Study, and were followed f

269 In the Netherlands, the incidence of meningococcal serogroup W

270 In a cross-sectional analysis in the Netherlands, the prevalence of type 2 diabetes among pat

271 tions diagnosed in Switzerland, Germany, the Netherlands, the UK, the USA, and Australia.

272 ort studies from ten countries (Iceland, the Netherlands, the USA, Taiwan, the UK, Germany, Finland,

273 tits (Parus major) in the United Kingdom and Netherlands to better understand how genetic signatures

274 ty (NESDA) and 1700 controls mainly from the Netherlands Twin Register (NTR).

275 ed for 8586 twins who were registered at the Netherlands Twin Register (women: 68.7%; mean +/- SD age

276 herlands Study of Depression and Anxiety and Netherlands Twin Register).

277 8 adolescent monozygotic twin pairs from the Netherlands Twin Register.

278 int, randomised trial at 60 hospitals in the Netherlands, UK, and France.

279 t pronounced in Western Europe (>60% for the Netherlands, United Kingdom, and Ireland) for both sexes

280 ) and Belgium (US $15,699), and lower in the Netherlands (US $10,936) and England (US $9342).

281 ve analysis, patients from 15 centres in the Netherlands, USA, Canada, Switzerland, UK, Italy, German

282 of Public Health at Erasmus Medical Center, Netherlands using the Microsimulation Screening Analysis

283 o stayed >48 hours in 2 tertiary ICUs in the Netherlands, using competing risk survival regression an

284 urrent girls-only vaccination program in the Netherlands, using the established STDSIM microsimulatio

285 ements taken at the study centre (Rotterdam, Netherlands) visits.

286 ry (n = 10,389) and strain collection in the Netherlands, we identified a set of 100 M. tuberculosis

287 ve patients with TRD from 2 hospitals in the Netherlands were enrolled between March 22, 2010, and Ma

288 duals belonging to 4 family cohorts from the Netherlands were included in the analyses.

289 of a tertiary care DED patient cohort in the Netherlands were included.

290 cruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a compute

291 Models from Basel and The Netherlands were validated against repeated 24 h outdoor

292 nally hypoxic marine basin (Grevelingen, The Netherlands), which suggest that the activity of cable b

293 red during the drilling of a gas well in The Netherlands, which led to the uncontrolled release of la

294 We included 59 HIV-infected AYAs from the Netherlands who had entered into pediatric care and tran

295 We enrolled 3905 persons in the Netherlands who had survived for at least 5 years after

296 erage-risk subjects (50-74 years old) in the Netherlands who were offered 4 rounds of FIT screening f

297 brand disease (VWD) in the Willebrand in the Netherlands (WiN) study by using the ratios of von Wille

298 2002 in the United States, Iceland, and the Netherlands with incident AF ascertained between 1987 an

299 tment in patients (aged >/=18 years from the Netherlands) with proximal arterial occlusion of the ant

300 MIG was safely introduced in the Netherlands, with overall morbidity and mortality compar